Health Condition 1: null- Heart Failure, Apelin
Conditions
Interventions
Intervention1: PTMC: Non pharmacoogical
Intervention2: Standard drugs: Diuretics, ACE inhibitors, beta-blockers in standard doses
Control Intervention1: NIL:
Sponsors
Department of Pharmacology AIIMSAnsari NagarNew Delhi
Eligibility
Inclusion criteria
Inclusion criteria: Adult male or female patients aged between 12 and 80 years Systolic or diastolic heart failure of NYHA class II or more Mitral stenosis patients posted for Percutaneous Transluminal Mitral Commissurotomy (PTMC) Healthy age matched controls with normal cardiovascular function
Exclusion criteria
Exclusion criteria: Diabetes mellitus Obesity Hypercholesterolemia Severe or uncontrolled hypertension Hepatic or renal failure Pregnant or lactating women (except for PTMC group) History of any acute coronary syndrome within previous one month
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in plasma apelin levels with therapy over a follow up period of 12 weeks.Timepoint: Baseline, 1 hour, 14-18 hours and at 12 weeks after PTMC in mitral stenosis patients undergoing the surgery. At baseline and after 12 weeks in other study groups, namely systolic heart failure, diastolic heart failure and healthy control groups. | — |
Secondary
| Measure | Time frame |
|---|---|
| -Plasma apelin levels in heart failure patients compared to normal controls at baseline. -Correlation between plasma apelin levels and plasma BNP levels, echocardiographic variables and quality of life parameters over a follow up period of 12 weeks. Timepoint: Baseline and at 12 weeks. | — |
Countries
India
Contacts
Public ContactDr Vinu Wilson
A.I.I.M.S.
Outcome results
None listed